Clinical trial for Relapsed or Refractory Multiple Myeloma
Official title A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov ID: NCT07681596
What this study is testing
What is AZD4045?
AZD4045 is an investigational biological therapy being studied for relapsed or refractory multiple myeloma.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether AZD4045 is safe and how well it works for people with relapsed or refractory multiple myeloma. It also looks at how the drug behaves in the body and other related questions.
- Who it's for
- You may be able to join if you are an adult with relapsed or refractory multiple myeloma and meet the study’s health criteria.
- What's involved
- You would receive AZD4045 alone or with daratumumab and aldesleukin. You will have regular visits for blood tests, scans, and other safety checks. The study team will monitor you closely for side effects.
- Time commitment
- The study lasts several months, with multiple clinic visits and tests scheduled throughout the treatment period.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participant must be 18 years or older at the time of signing the informed consent form.
- Participants must have documented diagnosis of MM according to the IMWG diagnostic criteria.
- Serum M-protein level ≥ 1.0 g/dL.
- Urine M-protein ≥ 200 mg/24 h.
- Serum immunoglobulin free light chain ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda free light chain ratio.
You likely can't join if
- Participant has a history of any grade IEC-HS and/or history of Grade ≥ 3 CRS and/or Grade ≥ 2 neurotoxicities during prior CAR-T cell therapy or T...
- Participant has ongoing toxicity from previous anti-cancer therapy that did not resolve to baseline levels or to Grade ≤ 1 with the exception of...
- Participant has a known active, or prior history of CNS involvement or exhibits clinical signs of meningeal involvement of MM.
- Participant has systemic immunoglobulin light chain amyloidosis, active plasma cell leukaemia (presence of ≥ 5% of circulating plasma cells on a...
- Participant has a history of haematologic malignancies, other than MM, regardless of remission status.
- Participant has a history of a prior non-haematologic malignancy unless the participant has been disease-free with no evidence of recurrence for ≥ 2...
See the full eligibility criteria
Who can join
- Participant must be 18 years or older at the time of signing the informed consent form.
- Participants must have documented diagnosis of MM according to the IMWG diagnostic criteria.
- Serum M-protein level ≥ 1.0 g/dL.
- Urine M-protein ≥ 200 mg/24 h.
- Serum immunoglobulin free light chain ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda free light chain ratio.
- ECOG performance score of 0 to 1.
- Participant must have screening bone marrow aspirate and/or archival sample adequate for clonal sequence calibration for MRD. An archival sample obtained from any time prior is acceptable.
- Participant must have adequate organ and bone marrow function.
- Participant must have received at least 3 prior classes of therapy, including a PI, an IMiD, and an anti-CD38 antibody
- Participant must have documented evidence of PD by IMWG 2016 criteria based on Investigator's determination during or after the most recent line of therapy
What rules you out
- Participant has a history of any grade IEC-HS and/or history of Grade ≥ 3 CRS and/or Grade ≥ 2 neurotoxicities during prior CAR-T cell therapy or T cell engaging therapy.
- Participant has ongoing toxicity from previous anti-cancer therapy that did not resolve to baseline levels or to Grade ≤ 1 with the exception of alopecia or peripheral neuropathy.
- Participant has a known active, or prior history of CNS involvement or exhibits clinical signs of meningeal involvement of MM.
- Participant has systemic immunoglobulin light chain amyloidosis, active plasma cell leukaemia (presence of ≥ 5% of circulating plasma cells on a conventional peripheral blood smear) at time of screening, Waldenstrom...
- Participant has a history of haematologic malignancies, other than MM, regardless of remission status.
- Participant has a history of a prior non-haematologic malignancy unless the participant has been disease-free with no evidence of recurrence for ≥ 2 years.
- Participant has significant neurological or psychiatric condition (active or history of).
- HIV (with exceptions)
- Chronic or active hepatitis B
- Active hepatitis C
- Myocardial infarction within 6 months prior to eligibility confirmation, or an unstable or uncontrolled disease/condition related to or affecting cardiac function.
- Uncontrolled cardiac arrhythmia or clinically significant ECG abnormalities.
- Congestive heart failure Class III or IV.
- Impaired cardiac function (LVEF \< 45%).
- Serious active or uncontrolled infection.
- Requirement of supplemental oxygen to maintain oxygen saturation.
- Active autoimmune disease or a history of autoimmune disease within 2 years.
- Inflammatory bowel disease requiring treatment within the past 5 years or other clinically significant gastrointestinal condition.
- Participant received live, attenuated vaccine within 28 days prior to eligibility confirmation
- Participant has undergone major surgery within 28 days prior to eligibility confirmation
- Concurrent enrolment in another clinical study (unless the study is observational, or the participant is in the follow-up period of an treatment study).
- Participant has a known life-threatening allergy, hypersensitivity, intolerance, or a contraindication to any study intervention or their excipients.
- Participant received any prior CAR-T or CAR-NK therapy directed at any target within 6 months prior to eligibility confirmation.
- Participant received any prior TCE therapy directed at any target within 6 months prior to eligibility confirmation.
- Participant received any prior BCMA-targeted treatment within 6 months prior to eligibility confirmation.
- Participant with a history of refractoriness to the most recent BCMA-targeted treatment received as defined as PD on or within 60 days of last dose or non-responsiveness (ie, did not achieve at least minimal response)...
- Participant received prior allogeneic stem cell transplant at any time.
- Participant received autologous stem cell transplant within 3 months prior to eligibility confirmation.
- Participant received radiation therapy for treatment of plasmacytoma within 14 days before eligibility confirmation.
- PI therapy.
- Monoclonal antibody treatment for MM.
- Cytotoxic therapy.
- Other systemic anti-myeloma therapy.
- Targeted therapy, epigenetic therapy, investigational drug or used an invasive investigational medical device.
The study team makes the final eligibility decision.
Where it is enrolling
- Duarte, California, United States
- Houston, Texas, United States
- East Melbourne, Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Duarte, California, United States; Houston, Texas, United States; East Melbourne, Australia. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.